English version Ukrainian version
Last issue Archive Editorial board Instructions to authors Contact us

This site supported by

Ukr. Bioorg. Acta 2020, Vol. 15, N1, 2-11


Anticancer evaluation of di- and trifunctional substituted 1,3-thiazoles

Kostyantyn V. Turov, Îleg P. Mitiukhin, Svitlana A. Chumachenko, Vladimir S. Zyabrev, Volodymyr S. Brovarets*

V.P. Kukhar Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, 1 Murmanska St., Kyiv, 02094, Ukraine.
e-mail: brovarets@bpci.kiev.ua

Anticancer activity of a series of polyfunctional substituted 1,3-thiazoles has been studied within the international scientific program “NCI-60 Human Tumor Cell Lines Screen”. Screening was performed in vitro on 60 cell lines of lungs, kidneys, CNS, ovaries, prostate, and breast cancer, epithelial cancer, leukemia, and melanoma. The most effective compounds were those with a piperazine substituent at C
2 of the 1,3-thiazole cycle: 1-(4-((4-methylphenyl)-sulfonyl)-2-phenyl-1,3-thiazol-5-yl)piperazine (average lg GI50 = -5.87, lg TGI = -5.54, lg LC50 = -5.21), 1-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-((4-methylpheyl)sulfonyl)-1,3-thiazol-5-yl)piperazine (average lg GI50 = -5.66, lg TGI = -5.26, lg LC50 = -4.83), and 1-(2,4-bis((4-methylphenyl)sulfonyl)-1,3-thiazol-5-yl)piperazine (average lg GI50 = -5.67, lg TGI = -5.21, lg LC5050 = -4.67).

1,3-thiazole; anticancer activity; growth inhibitor; cytostatic activity; cytotoxic activity

Full text: (PDF, in English)

1. Forlani, L.; Todesco, P. E., In Thiazole and Its Derivatives, Part 1, Metzger, J. V., Ed.; The Chemistry of Heterocyclic Compounds, Weissberger, A.; Taylor, E. C., Eds.; Wiley: New York, USA, 1979; Vol. 34, pp 567-571.
2. Medicines, Mashkovsky, M. D., Ed., New Wave: Moscow, 2005.

3. Ji, K.; Cho³, K.; Lee, S.; Park, S.; Khim, J. S.; Jo, E. H.; Choi, K.; Zhang, X.; Giesy, J. P. Effects of sulfathiazole, oxytetracycline and chlortetracycline on steroidogenesis in the human adrenocarcinoma (H295R) cell line and freshwater fish Oryzias latipes. J. Hazardous Materials 2010, 182, 494-502.
4. Felise, H. B.; Nguyen, H. V.; Pfuetzner, R. A.; Barry, K. C.; Jackson, S. R.; Blanc, M. P.; Bronstein, Ph. A.; Kline, T.; Miller, S. I. An Inhibitor of Gram-Negative Bacterial Virulence Protein Secretion. Cell Host & Microbe 2008, 4, 325-336.
5. Kovalishyn, V.; Grouleff, J.; Semenyuta, I.; Sinenko, V.; Slivchuk, S.; Hodyna, D.; Brovarets, V.; Blagodatny, V.; Poda, G.; Tetko, I.; Metelytsia, L. Rational design of isonicotinic acid hydrazide derivatives with antitubercular activity: Machine learning, molecular docking, synthesis and biological testing. Chem. Biol. Drug Des. 2018, 92, 1272-1278.
6. Mak, J. Y. W.; Xu, W.; Fairlie, D. P. In Peptidomimetics I, Lubell, W. D., Ed.; Springer, 2015; pp 235-266.
7. Alley, M. C.; Scudiero, D. S.; Monks, P. A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. Cancer Research 1988, 48, 589-601.
8. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. Seminars in Oncology 1992, 19, 622-638.
9. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Development Research 1995, 34, 91-109.
10. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nature Reviews 2006, 6, 813-823.
11. Turov, K. V.; Vinogradova, T. K.; Brovarets, V. S.; Drach, B. S. Reactions of 4-tosyl-2-phenyl-5-chloro-1, 3-thiazole with N-, O-, and S-nucleophiles. Russ. J. Gen. Chem. 2010, 80, 825-828.
12. Turov, K. V.; Vinogradova, T. K.; Rusanov, E. B. et al. Reaction of 1-tosyl-2,2-dichloroenamines with the Lawesson’s reagent. Russ.J.Gen.Chem. 2012, 82, 848-852.
13. Turov, K. V.; Drach. B. S. Reaction of 1-tosyl-2, 2-dichloroenamines with the Lawesson's reagent. Russ. J. Gen. Chem. 2008, 78, 629-633.
14. Turov, K. V.; Vinogradova, T. K.; Drach, B. S. Transformations of 5-chloro-2-hydrazino-4-p-tolylsulfonyl-1,3-thiazole. Russ. J. Gen. Chem. 2008, 78, 2132-2136.
15. Babii, S. B.; Zyabrev, V. S.; Drach, B. S. Cyclocondensation of 1-Tosyl-2,2-dichloroethenyl Isothiocyanate with O-, S-, N-, and C-Nucleophiles. Russ. J. Gen. Chem. 2002, 72, 1730-1735.

16. NCI-60 Human Tumor Cell Lines Screen. DTP Developmental Therapeutics Program, NIH website [Internet]. Available from:
https://dtp.cancer.gov/discovery_development/nci-60/default.htm. (accessed on March 20, 2020).